Seeking Alpha

Astellas reports Xtandi sales, Medivation rallies

  • Astellas Pharma (ALPMY) reports H1 consolidated net sales ( ¥ millions) of ¥556,702, up 16.7% Y/Y.
  • Net income ( ¥ millions) for H1 falls 16% Y/Y to ¥48.195. (full results)
  • Xtandi U.S. sales of ~$190M for April-September. (supplementary documents)
  • Backing out FQ1 sales of $82M gets ~$108M in U.S. Xtandi sales for FQ2.
  • These numbers are likely behind the rally in shares of Medivation (MDVN +10.1%), Astellas' Xtandi partner.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs